Pall Corporation to Acquire ATMI's LifeSciences Business for $185 million - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pall Corporation to Acquire ATMI's LifeSciences Business for $185 million

PTSM: Pharmaceutical Technology Sourcing and Management
Volume 10, Issue 1

Pall Corporation, a solutions provider in filtration, separation and purification, has signed a definitive agreement with ATMI to acquire ATMI’s LifeSciences business unit for $185 million. ATMI LifeSciences specializes in single-use bioprocess systems and consumables for the bio/pharmaceutical industry. According to the press release, the transaction is expected to close in Pall’s fiscal third quarter and will be subject to closing conditions, regulatory approvals and labor-related notifications.

Pall announced that for the balance of fiscal 2014, the company expects the acquisition to add $20 $30 million in revenue, be $0.05–$0.08 dilutive to EPS on a GAAP basis and almost breakeven on a cash EPS basis. Pall reaffirms its total overall fiscal 2014 guidance for pro forma EPS to be $3.30–$3.50.

Source: Pall Corporation

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here